Thermo Fisher Scientific Inc. $TMO Stock Holdings Decreased by Mountain Pacific Investment Advisers LLC

Key Points

• Mountain Pacific Investment Advisers LLC has reduced its stake in Thermo Fisher Scientific by 4.2%, owning 40,170 shares after selling 1,756 shares during the second quarter, valued at approximately $16.3 million.
• Thermo Fisher Scientific's stock has received multiple upgrades from analysts, including Barclays raising its price target from $490 to $550 and Royal Bank of Canada setting a target of $561. The consensus price target is currently $583.53.
• Insider selling has occurred, with CEO Marc N. Casper selling 10,000 shares for over $5 million, representing a 7.99% decrease in ownership, while total insider sales over the last ninety days amount to approximately $14.2 million.

Mountain Pacific Investment Advisers LLC decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 40,170 shares of the medical research company's stock after selling 1,756 shares during the period. Thermo Fisher Scientific comprises about 1.2% of Mountain Pacific Investment Advisers LLC's investment portfolio, making the stock its 29th biggest holding. Mountain Pacific Investment Advisers LLC's holdings in Thermo Fisher Scientific were worth $16,287,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CBIZ Investment Advisory Services LLC increased its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $30,000. Keystone Global Partners LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $31,000. DiNuzzo Private Wealth Inc. boosted its stake in Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock valued at $31,000 after acquiring an additional 61 shares during the period. Finally, IMA Advisory Services Inc. bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $35,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on TMO shares. Barclays upgraded Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $490.00 to $550.00 in a research report on Thursday, September 11th. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. HSBC reaffirmed a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $583.53.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 over the last ninety days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 9.6%

Shares of NYSE:TMO opened at $531.69 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a market capitalization of $200.77 billion, a price-to-earnings ratio of 30.75, a PEG ratio of 2.63 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $616.57. The company has a 50 day moving average price of $480.27 and a 200 day moving average price of $447.56.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.